Clinical trial · Observational
Impact of COVID-19 on GU Disease
Mitigating Risk of COVID-19 for Clinical Management of Genitourinary Diseases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. * Disclose if the patient has or had Genitourinary cancer or benign urologic condition * Provide urine specimen for research * Provide 4 tablespoons of blood for testing blood for research. * Provide permission to access medical records, such as patient lab results, medical history, imaging reports, etc.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Urologic Conditions | — | UNRESOLVED | — |
| COVID-19 Infection | — | UNRESOLVED | — |
| Genitourinary Cancer | Malignant Genitourinary System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- GU participants with active or past infection of SARS-Co-V-2
- description
- GU patients from medical records with active or past infection of SARS-Co-V-2
Primary outcomes (1)
- measure
- Proportion of patients with a new diagnosis of GU
- timeFrame
- Day 1
- description
- Proportion of patients with a new diagnosis of GU cancer and with active or past infection with SARS-Co-V-2
Secondary outcomes (2)
- measure
- Proportion of GU cancer patients, with active disease or in remission
- timeFrame
- Day 1
- description
- Proportion of GU cancer patients, with active disease or in remission and with active or past infection with SARS-Co-V-2
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects must be men and women 40 years of age or older * Subjects at risk or with GU cancer (Prostate, Bladder, Kidney) * Subjects with benign GU disorders ( BPH, UTI, Bladder infection and kidney stone) * Subjects must have a GU disease that requires clinic visit as determined by physician or healthcare provider following a telehealth appointment * Willing and able to provide blood and urine samples * Willing and able to complete a questionnaire to determine the COVID-19 symptoms. * Willing and able to sign informed consent form Exclusion Criteria: * Men and women below 40 years of age * Subjects do not have a GU disease
References
Publications (4)
- BACKGROUNDChakravarty D, Nair SS, Hammouda N, Ratnani P, Gharib Y, Wagaskar V, Mohamed N, Lundon D, Dovey Z, Kyprianou N, Tewari AK. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun Biol. 2020 Jul 8;3(1):374. doi: 10.1038/s42003-020-1088-9. PMID 32641750
- BACKGROUNDLundon DJ, Kelly BD, Nair S, Bolton DM, Kyprianou N, Wiklund P, Tewari A. Early mortality risk stratification after SARS-CoV-2 infection. Med Intensiva (Engl Ed). 2020 Jul 4;45(8):e40-2. doi: 10.1016/j.medin.2020.06.011. Online ahead of print. No abstract available. PMID 32912654
- BACKGROUNDPavlova IP, Nair SS, Kyprianou N, Tewari AK. The Rapid Coronavirus Antibody Test: Can We Improve Accuracy? Front Med (Lausanne). 2020 Sep 2;7:569. doi: 10.3389/fmed.2020.00569. eCollection 2020. No abstract available. PMID 32984390
- BACKGROUNDTheise ND, Arment AR, Chakravarty D, Gregg JMH, Jacobson IM, Jung KH, Nair SS, Tewari AK, Thurston AW, Van Drie J, Westover JB. Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2. Cell Cycle. 2020 Dec;19(24):3632-3638. doi: 10.1080/15384101.2020.1859752. Epub 2020 Dec 11. PMID 33305659